-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-07-15
Values as of: 2019-07-15
The investment seeks to replicate as closely as possible, before fees and expenses, the daily performance of the S&P 500? Equal Weight Index Total Return. The fund invests primarily in equity securities to meet its investment objective of replicating the underlying index as closely as possible, before fees and expenses. The underlying index is an unmanaged equal weighted version of the S&P 500? Index, which is an unmanaged capitalization weighted index comprised of 500 common stocks chosen by Standard & Poor's, a Division of The McGraw-Hill Companies, Inc. ("S&P") on a statistical basis. The fund is non-diversified.
Company Website : www.rydex-sgi.com/
Currency: USD
Country : USA
Inception Date: 24/04/2003
Primary Benchmark: S&P 500 Equal Weighted TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 0.4%
Management Expense Ratio: 0.20 %
N/A
N/A
Symbol | Company Name | Allocation |
---|---|---|
SCPS | Scopus Biopharma Inc | 0.23 % |
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
SOJE | SOJE | 0.00 % |
+0.04 (+0.21%) |
USD 65.72B |
JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.11 (-0.20%) |
USD 32.78B |
LCR | Leuthold Core ETF | 0.00 % |
-0.09 (-0.27%) |
USD 32.52B |
DTB | DTB | 0.00 % |
-0.12 (-0.63%) |
USD 26.58B |
DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.03 (-0.10%) |
USD 26.11B |
JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
N/A |
USD 22.47B |
SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.07 (-0.22%) |
USD 16.23B |
DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.04 (+0.10%) |
USD 10.15B |
AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+0.02 (+0.02%) |
USD 10.05B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
EVEN | 78.47 % | 0.00 % |
N/A |
N/A | |
SNAV | 28.01 % | 0.00 % |
N/A |
N/A | |
INAV | 23.00 % | 0.00 % |
N/A |
N/A | |
LEXI | Alexis Practical Tactical.. | 6.00 % | 0.00 % |
-0.09 (0%) |
USD 0.08B |
TBFG | The Brinsmere Fund - Grow.. | 3.14 % | 0.00 % |
-0.08 (0%) |
USD 0.27B |
QUS:AU | BetaShares S&P 500 Equal .. | 0.89 % | 0.00 % |
N/A |
USD 0.35B |
QEH | 0.00 % | 1.68 % |
N/A |
N/A | |
EQL:CA | Invesco S&P 500 Equal Wei.. | 0.00 % | 0.26 % |
-0.04 (0%) |
CAD 0.85B |
EQL-F:CA | Invesco S&P 500 Equal Wei.. | 0.00 % | 0.00 % |
N/A |
N/A |
EQL-U:CA | Invesco S&P 500 Equal Wei.. | 0.00 % | 0.00 % |
-0.03 (0%) |
N/A |
Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 19.97% | 79% | B- | 70% | C- | ||
Dividend Return | 1.06% | 49% | F | 33% | F | ||
Total Return | 21.03% | 79% | B- | 68% | D+ | ||
Trailing 12 Months | |||||||
Capital Gain | 5.17% | 75% | C | 69% | C- | ||
Dividend Return | 1.40% | 37% | F | 26% | F | ||
Total Return | 6.56% | 71% | C- | 63% | D | ||
Trailing 5 Years | |||||||
Capital Gain | 43.05% | 82% | B | 78% | C+ | ||
Dividend Return | 8.83% | 44% | F | 32% | F | ||
Total Return | 51.88% | 81% | B- | 76% | C+ | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 7.09% | 55% | F | 60% | D- | ||
Dividend Return | 8.66% | 49% | F | 59% | D- | ||
Total Return | 1.56% | 52% | F | 41% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 8.90% | 36% | F | 88% | B+ | ||
Risk Adjusted Return | 97.30% | 51% | F | 92% | A | ||
Market Capitalization | 10.83B | 97% | N/A | 89% | A- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.